Answers are grounded in this paper and cite their sources.
The safety and efficacy of neoadjuvant immunochemotherapy (nICT) for locally advanced gastric cancer (LAGC) remain controversial.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: